331 results about "Vascular Disorder" patented technology

The invention relates to the field of small cerebral vessels, in particular to a medical image-based early feature analysis method and system for small cerebral vessels. The method comprises the following steps: acquiring a brain magnetic resonance image data set, preliminarily analyzing brain small vessel local features based on the brain magnetic resonance image data set, and generating a basic brain small vessel feature set; obtaining a clinical parameter set of the patient, analyzing the recessive influence factors according to the clinical parameter set of the patient, and generating a brain small vessel optimized feature set based on the basic brain small vessel feature set and in combination with the recessive influence factors; and performing visual fusion rendering according to the brain small vessel optimized feature set, and generating and outputting a record analysis log. In the process of early feature analysis of small cerebral vessels, doctors are assisted in accurately identifying the enlargement of the gaps around the vessels and simulators thereof, the misjudgment risk is effectively reduced, and the accuracy and reliability of early diagnosis of small cerebral vessel diseases are improved.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

A prediction system includes: a terminal; and a processor, communicatively coupled to the processor. The processor is configured to: acquire medical treatment information including images captured at at least one of before, during, immediately after, and after a predetermined period from treatment of a patient with a symptom of a vascular disease; classify a condition of the patient based on a classification image; learn the medical treatment information in association with the condition of the patient; and predict at least one of a treatment effect and a prognosis when treatment intervention is performed for the patient based on a learning result.

Use of an NLRP3 inhibitor for treating cerebrovascular diseases. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating cerebrovascular diseases, wherein each substituent is as defined in the description.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present invention are co-crystals of Uric Acid with increased solubility with respect to crystals of Uric Acid, suitable for the pharmaceutical use. The invention comprises co-crystals with L-lysine, L-arginine, ethylene diamine, and tromethamine as co-formers, pharmaceutical compositions thereof and their therapeutical use in the prevention or treatment of cerebrovascular diseases.

In one aspect, the disclosure relates to a method for treating clonal hematopoiesis of indeterminate potential (CHIP) in a subject, the method including at least the step of administering to the subject a therapeutically effective amount of an inhibitor of receptor activator of nuclear factor κB ligand (RANKL), such as denosumab, a therapeutically effective amount of an anti-inflammatory agent, such as colchicine, or both. In a further aspect, performing the method reduces growth of one or more clones or causes the size of one or more clones to remain constant. In another aspect, each month of performing the method can result in a further reduction of annual clonal growth rate. In a still further aspect, performing the method further treats or prevents a cardiometabolic disease, a cardiovascular disease, or a myeloproliferative disease or disorder. Also disclosed are methods for reducing or maintaining clonal hematopoiesis risk score (CHRS) in a subject.

The invention relates to an intelligent monitoring and risk early warning system for cardiovascular acute and critical diseases, which is characterized in that electrocardiosignals are acquired in real time through a wearable twelve-lead ECG monitor (ADS1298 chip, 512Hz sampling), and the electrocardiosignals are encrypted and transmitted to a cloud end through an MQTT protocol in combination with edge end wavelet denoising and QRS wave detection. And the cloud end adopts a multi-modal fusion engine, integrates a random forest-XGBoost hybrid model, performs modeling based on a postoperative patient physiological index time sequence, predicts the risk through Kalman filtering and triggers secondary early warning. Clinical tests in a third-A hospital prove that the end-to-end response time is 2.8 seconds, the D2B time is shortened to 70 minutes, and the occurrence rate of main adverse cardiovascular events in 30 days after operation is reduced by 47%. According to the invention, the limitation of traditional single-mode monitoring is broken through, a whole-process closed loop of collection-analysis-intervention is constructed, and an intelligent solution is provided for prevention and control of cardiovascular acute and critical diseases.

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

A pro-inflammatory and vasoconstrictor and endothelin-1 (ET-1) are pathogenic molecules related to a series of cardiovascular diseases. Unlike ET-1 signaling for vasoconstriction of the main artery, we have proven herein that coronary microvessels exhibit a unique signaling mechanism for constriction (independent of PKC, CPI-17, and intracellular calcium storage). The pathophysiological level of ET-1 acts preferentially on the microvessels to exert persistent vasoconstriction by activating Rho kinase upon binding to ETAR of the ET-1 receptor. The ETAR antagonist BQ123 only blocks but cannot reverse vasoconstriction against ET-1. In contrast, ROCK inhibitors (e.g., H-1152) are effective to reverse arteriolar systole against ET-1. Thus, ROCK inhibition is a potent and specific choice for the treatment of coronary ischemic disease (abnormal vasoconstriction) associated with microvascular dysfunction due to excessive production of ET-1. The ROCK inhibitors may also be used to treat microvascular diseases associated with diabetic retinopathy as well as microvascular dysfunction caused by cancer therapy or immunosuppressive drugs. Since H-1152 can also reduce the basal tension of microvessels, a ROCK inhibitor is also a good diagnostic agent when used during angiography or by a non-invasive method.

Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting human ANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.

The present invention provides a pharmaceutical composition comprising a) a first phase comprising rosuvastatin, and b) a second phase comprising acetylsalicylic acid, wherein the first phase comprising rosuvastatin is in the form of a coated tablet, and the second phase comprising acetylsalicylic acid is in the form of granules; said pharmaceutical composition solves a set of significant technological challenges due to the physicochemical properties and difference in dosage of each drug. The pharmaceutical composition of the present invention is stable, and also has a comparative bioavailability equivalent to that of the co-administered monodrugs, so that the composition is safe and effective in the treatment of hyperlipidemias and in the prevention of at least one cardiovascular disease. The invention is also directed to a process for manufacturing the pharmaceutical composition.

This invention relates to inhibitors of nitrogen-containing heterocyclic derivatives, their preparation methods, and applications. In particular, this invention relates to compounds of general formula (I), their preparation methods, pharmaceutical compositions containing such compounds, and their use as inhibitors in the treatment of cardiovascular and cerebrovascular diseases, wherein the substituents in general formula (I) are the same as defined in the specification.

The present disclosure relates to engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperones derived from apolipoprotein M (ApoM)-Fc fusion proteins with extended half-life in vivo. The disclosed ApoM-Fc fusion proteins provide a safe, highly efficient and effective way of delivering S1P to endothelial cells and all tissues of the body.

The invention belongs to the field of medicine, and relates to a Keap1 degradation agent and a preparation method and application thereof, the Keap1 degradation agent is a compound shown in the formula I or pharmaceutically acceptable salt, optical isomer, stereoisomer or metabolite of the compound, and further, the invention further discloses application of the compound and a pharmaceutical composition of the compound in preparation of a medicine serving as the Keap1 degradation agent, and application of the Keap1 degradation agent in preparation of the medicine serving as the Keap1 degradation agent in preparation of the medicine serving as the Keap1 degradation agent in preparation of the medicine serving as the Keap1 degradation agent. The compound can be used for treating metabolic diseases, cardiovascular diseases, rheumatoid arthritis or steatohepatitis.

Provided are gene editing systems and methods for treating cardiovascular disease (CVD). Also provided are polynucleotides, vectors, cells, kits and compositions comprising the components of the gene editing systems, and methods related to treatment of CVD.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

This invention discloses the application of 12S-HHT in the preparation of drugs for the prevention and / or treatment of cardiovascular diseases. The study found that after administration, 12S-HHT acts as a signaling molecule in vivo, activating the PPARδ signaling pathway and regulating the expression of a series of downstream genes related to energy metabolism and mitochondrial function, thereby achieving a therapeutic effect. Mechanism of action: By binding to and activating PPARδ, it upregulates its downstream target genes. ANGPTL1 It promotes fatty acid oxidation and enhances the "metabolic flexibility" of myocardial cells.

The present disclosure provides compounds capable of exhibiting effects similar to those of 2-Cys-peroxyredoxin (2-Cys-Prx) in the body with excellent pharmacological effects and reduced side effects such as reduced cytotoxicity, and pharmaceutical uses thereof. The compounds of the present disclosure and their pharmaceutically acceptable salts are useful for the treatment or prevention of vascular diseases, particularly ischemic coronary artery disease, arteriosclerosis, vascular restenosis, or pulmonary arterial hypertension. The compounds of the present invention and their pharmaceutically acceptable salts are particularly useful for the treatment or prevention of pulmonary arterial hypertension. The invention also provides methods of preparing the compounds of the present disclosure.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention discloses a cerebrovascular disease risk prediction method, and particularly relates to the field of disease risk prediction, and the method comprises the following steps: S1, collecting basic clinical data, dynamic physiological parameter data and image feature data of a target object, and constructing a data set; s2, performing feature extraction on the basic clinical data, the dynamic physiological parameter data and the image feature data, and fusing the extracted features to obtain a fused feature set; s3, constructing a fusion prediction model through the fusion feature set; and S4, inputting the data set into the fusion prediction model, and outputting a risk prediction result. According to the method, the information short board of a single data type is made up, different types of data are converted into a unified computable form through standardized quantitative processing, core information with risk indication significance is effectively screened out in combination with abnormal data proportion analysis and dynamic fluctuation intensity evaluation, and the recognition capability of early potential risks of diseases is remarkably improved.

The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia / reperfusion (I / R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RARβ) agonist.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

The present application relates to the technical field of medical monitoring, in particular to a vascular hemodynamic abnormality monitoring system and a pulse wave analysis method thereof, the core of the present application lies in that a flexible piezoelectric sensor array is used to capture human vascular pulse wave signals, the signals are transmitted to a wearable monitoring device for preliminary preprocessing, and then transmitted to a data processing host through a wireless manner, a pulse wave analysis module in the host adopts a multi-level analysis method, including multi-scale signal decomposition and reconstruction, nonlinear feature extraction and pattern recognition, multi-parameter adaptive judgment standard, deep learning feature automatic extraction and multi-site information fusion decision, ensuring the accuracy and comprehensiveness of the analysis, finally, the processing result is transmitted to an application platform to generate a vascular health report, realizing non-invasive continuous monitoring, this innovation effectively fills the gap of the prior art in continuous monitoring, and has important significance for real-time monitoring of vascular health status and prevention of vascular diseases.

The present invention relates to a class of monoclonal antibodies having anti–von Willebrand factor (VWF) effects, and a use thereof. A pharmaceutical composition of the monoclonal antibodies or antigen-binding fragments having anti–von Willebrand factor effects provided by the present invention can be used to reduce VWF levels in the body, thereby preventing and treating thrombotic microangiopathies having various causes (including thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and atypical hemolytic-uremic syndrome), cardiovascular disease, stroke, atherosclerosis, senile dementia, vascular dementia, and bacterial and viral infectious diseases.

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.